Advanced

MICRODOSING FOR EARLY BIOKINETIC STUDIES IN HUMANS.

Stenström, Kristina LU ; Sydoff, Marie LU and Mattsson, Sören LU (2010) In Radiation Protection Dosimetry 139. p.348-352
Abstract
Microdosing is a new concept in drug development that-if implemented in the pharmaceutical industry-would mean that new drugs can be tested earlier in humans than done today. The human microdosing concept-or 'Phase 0'-may offer improved candidate selection, reduced failure rates in the drug development line and a reduction in the use of laboratory animals in early drug development, factors which will help to speed up drug development and also reduce the costs. Microdosing utilises sub-pharmacological amounts of the substance to open opportunities for early studies in man. Three technologies are used for microdosing: accelerator mass spectrometry (AMS), positron emission tomography and liquid chromatography-tandem mass spectrometry. This... (More)
Microdosing is a new concept in drug development that-if implemented in the pharmaceutical industry-would mean that new drugs can be tested earlier in humans than done today. The human microdosing concept-or 'Phase 0'-may offer improved candidate selection, reduced failure rates in the drug development line and a reduction in the use of laboratory animals in early drug development, factors which will help to speed up drug development and also reduce the costs. Microdosing utilises sub-pharmacological amounts of the substance to open opportunities for early studies in man. Three technologies are used for microdosing: accelerator mass spectrometry (AMS), positron emission tomography and liquid chromatography-tandem mass spectrometry. This paper focuses on the principle of AMS and discusses the current status of microdosing with AMS. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Radiation Protection Dosimetry
volume
139
pages
348 - 352
publisher
Nuclear Technology Publishing
external identifiers
  • WOS:000277738200066
  • PMID:20167793
  • Scopus:77953353160
ISSN
1742-3406
DOI
10.1093/rpd/ncq029
project
MERGE
language
English
LU publication?
yes
id
cf642926-7863-4588-a78c-0a03455c3a83 (old id 1552518)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/20167793?dopt=Abstract
date added to LUP
2010-03-03 13:43:02
date last changed
2016-10-13 04:23:40
@misc{cf642926-7863-4588-a78c-0a03455c3a83,
  abstract     = {Microdosing is a new concept in drug development that-if implemented in the pharmaceutical industry-would mean that new drugs can be tested earlier in humans than done today. The human microdosing concept-or 'Phase 0'-may offer improved candidate selection, reduced failure rates in the drug development line and a reduction in the use of laboratory animals in early drug development, factors which will help to speed up drug development and also reduce the costs. Microdosing utilises sub-pharmacological amounts of the substance to open opportunities for early studies in man. Three technologies are used for microdosing: accelerator mass spectrometry (AMS), positron emission tomography and liquid chromatography-tandem mass spectrometry. This paper focuses on the principle of AMS and discusses the current status of microdosing with AMS.},
  author       = {Stenström, Kristina and Sydoff, Marie and Mattsson, Sören},
  issn         = {1742-3406},
  language     = {eng},
  pages        = {348--352},
  publisher    = {ARRAY(0xb69f6d8)},
  series       = {Radiation Protection Dosimetry},
  title        = {MICRODOSING FOR EARLY BIOKINETIC STUDIES IN HUMANS.},
  url          = {http://dx.doi.org/10.1093/rpd/ncq029},
  volume       = {139},
  year         = {2010},
}